Sun Pharmaceutical Industries Limited (SUNPHARMA) Q1 Results FY27 Preview: Date, Time, Expectations & Key Things To Watch

CompoundingAI Research Updated July 26, 2026 4 min read

Sun Pharmaceutical Industries Limited enters the Q1 FY 2026-2027 results facing a critical test of its specialty-led growth strategy against a backdrop of persistent US generic pricing pressures. Investors will be focused on the recovery trajectory of EBITDA margins following a notable Q4 dip and the progress of high-growth innovative launches like LEQSELVI and UNLOXCYT.

Quick Details

Results date	July 31, 2026
Quarter	Q1 FY 2026-2027
Previous quarter revenue	Rs. 14,611.79 Cr
Previous quarter PAT	Rs. 2,714.03 Cr
Previous quarter EBITDA margin	27.1%
Market cap	Rs. 465,734.91 Cr
CMP	Rs. 1941.1

Sun Pharmaceutical Industries Limited Q1 Results Date and Time

The board meeting is scheduled for 31 July 2026 to approve the Q1 FY27 unaudited results.

What to expect from Sun Pharmaceutical Industries Limited's Q1 FY27 results

Sun Pharma's Q1 FY27 performance will be evaluated against management's high single-digit consolidated revenue growth guidance for the full year. The company's India formulations business, which grew at 6% volume in Q4 FY26, continues to be a primary growth pillar, while the US generics segment remains constrained by specific product competition and regulatory compliance overheads at the Halol, Mohali, and Dadra facilities. A weaker rupee, with a floor near 94.00-94.50 against the USD, provides a translation tailwind to INR-reported revenues compared to the year-ago period. Management has signaled that the elevated base spending for specialty launches like LEQSELVI and UNLOXCYT is now structural, making the EBITDA margin recovery from the Q4 FY26 level of 27.1% a key indicator of operational efficiency. The upcoming call will likely address the impact of the 30 June 2026 DPCO amendment on India pricing and the medium-term implications of the US tariff policy, which currently exempts generics through 2028.

Key Things To Watch

Performance vs Guidance Tracking: Tracking key FY27 targets against Q1 results.

Consolidated Topline Growth — high single-digit target for FY27
R&D Spend — 6% to 7% of sales target for FY27
Effective Tax Rate — ~25.168% target under Section 115BAA

Specialty Product Commercial Progress: Monitoring the ramp-up of innovative medicines.

LEQSELVI: Prescription volumes and reimbursement trends post-April 1 access expansion
UNLOXCYT: Launch trajectory and patient starts in the US
ILUMYA: Update on the sBLA for psoriatic arthritis indication

USFDA Compliance and Regulatory Overhang: Status of manufacturing facility remediation.

Halol: Awaiting FDA re-inspection following completion of CAPA
Mohali and Dadra: Ongoing implementation of corrective and preventive actions
Impact on ANDA approval pace and new generic product launches

Strategic M&A Updates: Integration and closure timelines for recent acquisitions.

Organon & Co.: Status of remaining regulatory approvals with expected close in Q4 FY27
Innovcare Lifesciences: Closure update for the Rs. 271.2 Cr cash acquisition

Risks and headwinds to monitor: External factors impacting the business environment.

NPPA DPCO Amendment (30 June 2026): Potential pricing impact on India Formulations
US Tariff Policy: Monitoring the medium-term overhang of potential 2028 tariffs on generics

Frequently Asked Questions

What was the primary driver of Sun Pharma's Q4 FY26 margin decline?

Management attributed the Q4 FY26 EBITDA margin decline to 27.1% to lower milestone income and seasonality. Expenses related to new specialty launches like LEQSELVI and UNLOXCYT were also fully factored into the base spend.

How is Sun Pharma addressing the US generics business slowdown?

Management noted that the slowdown is due to specific competition for certain products and ongoing compliance issues that have delayed new approvals. The company is focusing on an active life cycle management approach and increasing investment in the specialty pipeline to sustain growth.

What is the status of the Organon & Co. acquisition?

Stockholders approved the merger on 24 July 2026, making Organon a wholly owned subsidiary. The transaction remains subject to customary closing conditions, with management expecting the deal to close in Q4 FY27.

Is Sun Pharma on track with its R&D spending guidance?

For FY26, the company achieved its R&D spend target of approximately 6% of sales. Management has guided for an R&D spend of 6% to 7% of sales for FY27.